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 Introduction 
 Inflammatory bowel disease (IBD) affects a substan-
tial number of patients during their peak reproductive 
years. With an estimated prevalence of 1 for 1,000 inhab-
itants in Europe, Crohn’s disease (CD) and ulcerative 
colitis (UC) affect both sexes equally (the female to male 
ratio in major epidemiological studies varies from 0.51 to 
1.58 and 0.34 to 1.65 for UC and CD, respectively  [1] ). 
Around half of all IBD patients are diagnosed before the 
age of 35 years  [2] , and about a quarter of patients are di-
agnosed before their first conception  [3] . Accordingly, a 
significant number of questions and uncertainties have 
arisen for this population, with regard to the risk of trans-
mission of IBD to the offspring, the impact of the disease 
and the therapies on fertility, the role of the disease on the 
course of the pregnancy and the mode of delivery, and 
finally, the impact of therapies on pregnancy, fetal devel-
opment and breastfeeding. 
 The safety of medical therapy during pregnancy and 
lactation is a major concern for both pregnant women 
and their partners as well as for the physicians involved 
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 Abstract 
 Inflammatory bowel disease (IBD) is frequent in women dur-
ing their peak reproductive years. Accordingly, a significant 
number of questions and uncertainties arise from this popu-
lation regarding the risk of transmission of IBD to the off-
spring, the impact of the disease and therapies on the fertil-
ity, the role of the disease on the course of the pregnancy 
and the mode of delivery, the impact of the therapy on the 
pregnancy and fetal development as well as breastfeeding. 
The safety of medical therapy during pregnancy and lacta-
tion is a major concern for both pregnant women and their 
partners as well as for physicians. As a general rule, it can be 
stated that the benefit of continuing medical therapy in IBD 
during pregnancy outweighs the potential risks in the vast 
majority of instances. This article will review recent develop-
ments on this topic consistent with the European Crohn’s 
and Colitis Organization guidelines. 
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in their treatment, such as obstetricians, general practi-
tioners and gastroenterologists. Ideally, all women of re-
productive age should receive pregnancy counseling (i.e. 
it should not only be offered after conception), in order to 
ascertain optimal disease control, to adapt a therapy if 
necessary and to ensure adequate nutritional status and 
supplementation.
 In view of accumulated observational data from the 
literature on IBD in recent years, the following essential 
rule can be derived: the benefit of continuing medical 
therapy in IBD during pregnancy outweighs the potential 
risks in most instances  [4–11] .
 This article, consistent with the European Crohn’s and 
Colitis Organization (ECCO) guidelines, reviews the lit-
erature with regard to recent developments on the subject 
in order to help provide clear information to patients. 
 IBD and Heredity 
 Among the identified risk factors for IBD, such as 
smoking, ethnicity or appendectomy, cohort studies and 
family registries have observed that a positive family his-
tory is considered the likeliest to predict lifetime risk  [7, 
12] . The prevalence proportion ratios (division of ob-
served IBD cases with expected cases in this population) 
are constantly higher amongst the offspring of CD pa-
tients  [13] ; this is also illustrated by the higher concor-
dance rates for CD in twin studies  [14] . The risk of trans-
mission was found to be higher from mother to child than 
father to child in non-Jewish patients with CD; this dis-
tortion of transmission on the basis of sex was not ob-
served in UC  [15] . Compared to the normal prevalence, 
an approximately 10-fold increased risk for UC and CD 
was identified in a Danish study among the first-degree 
relatives of IBD patients  [16] . A consecutive nationwide 
study identified prevalence proportion ratios of 2.6 for 
CD and 5.1 for UC in UC patients and 12.8 for CD and 
4.0 for UC in CD patients, respectively  [13] . When one 
parent is affected, the overall risk of IBD in the offspring 
appears to be 2–13 times higher than in the general pop-
ulation  [13, 16, 17] . The risks of transmission appears to 
be higher in CD than in UC, estimated to be 5.2 and 1.6%, 
respectively, for the occurrence of IBD in the offspring of 
one affected parent. These risks are even higher in the 
Jewish population, and increase to 7.8 and 4.5%, for CD 
and UC, respectively. If both parents of an individual 
have the disease, the risk of occurrence of an IBD during 
their lifetime rises to 36%  [18] .
 IBD and Fertility 
 Infertility is usually defined as the failure to conceive 
after 1 year of unprotected regular sexual intercourse. In 
general, IBD patients have fewer children than the gen-
eral population. An adequate interpretation of the data 
on IBD patient fertility is hampered by the fact that some 
patients choose to not conceive, for a variety of reasons, 
such as concerns about their disease being inherited, a 
fear of teratogenicity of the medication, the impairment 
of general activity and their social and sexual life. The 
impact of medical advice against pregnancy with IBD 
from the lay literature or treating physicians  [19] is also a 
factor. However, nowadays, there is a general consensus 
that overall, both male and female fertility is not signifi-
cantly affected in nonoperated IBD patients when their 
disease is quiescent  [20–23] . Population studies  [6, 7] in 
CD estimate the rate of female infertility at 5–14% in pa-
tients in remission, which is similar to rates observed in 
the general population. On the other hand, an active dis-
ease decreases fertility significantly, via an inflammation 
which extends to the tubo-ovarian system, surgical se-
quels (adherences in the pelvis), a secondary amenorrhea 
or sexual dysfunction (frequent in the presence of ano-
perineal lesions). In UC, a significant drop in fertility rate 
is observed in women after proctocolectomy with ileal 
pouch anal anastomosis (IPAA). This impairs fertility 
significantly; decreases of up to 80% have been described 
 [24, 25] . Other studies confirm these results  [26] , showing 
an infertility rate that increased from 13.3 to 38.6% (p  ! 
0.001) after IPAA. However, this is ostensibly a mechani-
cal infertility, and in vitro fertilization seems to be a valu-
able alternative to enable these women to conceive  [27] . 
According to more recent studies, this impairment ap-
pears to be less profound. The time to successful concep-
tion after IPAA was shown to be significantly prolonged, 
but the absolute rates of conception were only moderate-
ly decreased with 72 and 88% of women having under-
gone IPAA and a non-IBD control, respectively, which 
points to a reduced probability of conception rather than 
to complete infertility  [28, 29] . The logical choice of a lap-
aroscopic procedure in order to reduce the risk of adhe-
sions has recently demonstrated its efficacy compared to 
laparotomy  [30] . Medical therapy does not appear to have 
a negative impact on reproduction  [23] , with the excep-
tion of the drug sulphasalazine. The nontherapeutic sul-
phapyridine content may induce oligospermia and ad-
verse sperm motility and morphology  [31, 32] . This effect 
is dose-dependent and is fully reversible 6 months after 
stopping the drug or switching to 5-ASA  [33] . Other ami-
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nosalicylates do not induce this effect. Methotrexate 
(MTX) is also a source of oligospermia which is reversible 
after a discontinuation of the therapy (this has to occur 
at least 4 months before conception). 
 The Effect of Pregnancy on the Course of IBD 
 When conception takes place during a period of qui-
escent disease, the probability of a flare during pregnan-
cy is similar to the expected risk of a flare in nonpregnant 
women with CD and UC over a period of 9 months  [34, 
35] . Indeed, UC studies  [36] report an annual exacerba-
tion rate of 34% during pregnancy versus 32% out of preg-
nancy. The exacerbation rates for CD during a pregnancy 
or at other times were similar  [37] . However, in both UC 
and CD, when conception occurs while the disease is ac-
tive, it is estimated that two thirds of patients will have 
active disease during the pregnancy, and that two thirds 
of these, in turn, will present a worsening of the flare.  [20, 
22] . This underlines that achieving and maintaining re-
mission prior to conception is of upmost importance  [4, 
7, 8, 37, 38] .
 The overall course of disease during pregnancy seems 
to be slightly milder in CD, although confounding factors 
such as smoking cessation may also play a role here  [39] . 
In both CD and UC, a decrease in the rate of flares was 
observed in a 3-year  [40] and in a 10-year  [41] follow-up. 
Although these observations are in line with those for 
other immune diseases, the mechanisms behind a poten-
tial beneficial effect of pregnancy on disease course still 
remain to be elucidated. One explanation might be im-
munosuppression induced by a disparity of the human 
leukocyte antigens (HLA II), DRB1 and DQ between 
mother and fetus  [42] .
 Effect of IBD on Pregnancy Outcome, Fetal 
Evolution and Neonatal Prognosis 
 Multiple population studies suggest that IBD per se, 
independently from the disease activity level, is linked to 
an increased rate of pregnancy complications  [43–46] . 
Indeed, the risk of preterm birth [i.e. birth before gesta-
tional week (GW) 37], low birth weight ( ! 2,500 g), small-
for-gestational-age babies and fetal losses (spontaneous 
or therapeutic)  [35] were observed significantly more of-
ten in IBD patients than in the general population, with 
odds ratios between 1.4 and 2.2  [45] . It appears that the 
previously reported increased frequency of therapeutic 
abortions in IBD patients was rather related to psychoso-
cial stress (coping with a double burden – chronic disease 
and offspring) or a fear of severe side effects from medical 
therapy  [46, 47] . However, according to more recent data 
from Europe  [11] and the USA  [48] , there is no increase 
in spontaneous or therapeutic abortion in women with 
IBD.
 There is likely no increased risk of congenital malfor-
mations in the IBD population  [49] . Resection surgery 
and disease of the ileum in the past were shown to be risk 
factors for a pregnancy course with complications  [48, 
50] . It is crucial to ensure these patients receive close ob-
stetrical and fetal monitoring, especially if conception 
occurred when the disease was active. 
 Concerning the risk of maternal complications rela-
tive to pregnancy and labor (e.g. placental disruption, ec-
lampsia or placenta previa), the data available do not en-
able a clear conclusion. The neonatal prognosis of infants 
born at term does not seem to be affected by the presence 
of IBD in the mother  [48] .
 Any pregnancy occurring in an IBD patient should be 
considered as a high-risk pregnancy. It is thus crucial to 
ensure that these patients receive the close monitoring of 
a multidisciplinary team consisting of an obstetrician, a 
gastroenterologist, a visceral surgeon and a proctologist).
 Mode of Delivery 
 Women with IBD more commonly undergo Cesarean 
section than the average population  [51] ; however, there 
is no firm evidence advocating it as the preferred mode 
of birth for these women. The decision to undergo a Ce-
sarean section should rely on strictly obstetrical indica-
tions, with the exception of three conditions which rep-
resent contraindications to a vaginal delivery: active peri-
anal CD, active rectal disease and in UC patients who 
have undergone a colectomy with IPAA  [7, 34, 51] . In 
IPAA, the already challenged maintenance of continence 
heavily relies on an appropriate sphincter ani function, 
which is threatened by the mechanical forces involved in 
vaginal birth. An episiotomy should be avoided when-
ever possible in CD patients, as cases of secondary ano-
perineal lesions occur  [52] . The presence of a colostomy 
or ileostomy is not a contraindication for a vaginal deliv-
ery. The basis for the decision regarding mode of delivery 
is the obstetric necessity, with individual patient prefer-
ences and interdisciplinary consensus between the vis-
ceral surgeon and the gastroenterologist being other 
components.
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 Endoscopy and Surgery during Pregnancy 
 Although concerns with regard to the safety of endo-
scopy during pregnancy are notoriously raised, this pro-
cedure generally appears to be safe and may be performed, 
presuming that there is a strong indication such as sig-
nificant bleeding. If possible, colonoscopy should be per-
formed in the second trimester. To avoid vena cava com-
pression, which can impair uterine blood flow and cause 
fetal hypoxemia, the pregnant patient in the second and 
third trimester should be positioned in the left lateral or 
left pelvic-tilt position  [34] . Performance or at least plan-
ning of the procedure should occur in conjunction with 
obstetrical support, including documentation of fetal 
heart beat prior to, during and after the endoscopy. If a 
minimal dose of sedation is used to ensure adequate com-
fort of the patient under appropriate monitoring, propo-
fol and meperidine (both class B) appear to be relatively 
safe. Benzodiazepines (class D) should not be used espe-
cially in the first trimester, as these substances have been 
associated with congenital cleft palate  [53] . 
 Surgery may be indicated in UC (for refractory acute 
severe colitis requiring colectomy) and CD (for perfora-
tion, abscesses, severe hemorrhage or obstruction) in preg-
nant women. When there is an appropriate indication, the 
risk of the ongoing illness generally outweighs the peripro-
cedural risk for the fetus  [4] . In non-life-threatening cases, 
a carefully balanced approach in intensifying medical 
treatment to avoid surgery may be appropriate  [7] . With 
endoscopy, there are concerns about spontaneous abor-
tion (first trimester) or induction of preterm labor (third 
trimester). However, due to the emergent setting, post-
ponement to the second trimester or postpartum are not 
possible in the majority of instances  [54] . A temporary il-
eostomy is advocated instead of primary anastomosis  [54] .
 Medical Therapy during Pregnancy and 
Breastfeeding 
 As a general rule, medical therapy for CD and UC 
should generally be continued during pregnancy as the 
benefits of stable remission for the mother and fetus 
largely outweigh the potential risks in most cases  [4–11] . 
In other words: it is the active disease that poses the great-
est risk for the mother and unborn child, not the medical 
therapy. However, there are no drugs used to treat gastro-
intestinal diseases with pregnancy category A [Food and 
Drug Administration (FDA) pregnancy categories are 
depicted in  table 1 ], implying that the use of any medical 
treatment option for IBD in pregnancy is at best associ-
ated with a remote but possible chance of fetal harm. 
Hence, the slight potential or theoretical risk that re-
mains must be discussed with the mother and preferably 
both parents individually.
 It is paramount to note that with regard to drug safety 
in pregnancy, the number of high-quality studies (i.e. con-
trolled trials) is very limited and that most of the human 
data available originates from large retrospective databas-
es or case series. Concerning animal models, it has to be 
borne in mind that neither safety nor harm observed in 
animals necessarily translates to a similar outcome in hu-
Table 1. F DA pregnancy categories
FDA pregnancy
category
Controlled studies
in pregnant women
Controlled studies 
in animals
Comment
A +, no risk +, no risk Possible fetal harm is remote
B – +, no risk Chance of fetal harm is still remote, but remains a possibility
+, no risk +, adverse effect
C – +, adverse event Chance of fetal harm. Use only if potential benefit outweighs risk
– –
D –, but evidence 
for risk or
–, but evidence for risk Benefit may sometimes outweigh risk (i.e. when disease is life-
threatening and there are no effective alternative drugs available)
X +, risk demonstrated +, risk demonstrated Drug contraindicated (also in nonpregnant women who may 
become pregnant)
+ = Available; – = unavailable.
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mans. A significant number of women do not recognize 
pregnancy up to weeks 6–8, when organogenesis is already 
mostly completed; this underlines that the optimal time to 
discuss medical therapy is certainly prior to conception.
 Lactation itself does not seem to independently affect 
the course of disease in IBD  [34] . The necessity of weigh-
ing up risks and benefits also applies to breastfeeding, 
where the availability of human data is even more limit-
ed. Uncertainty and the fear of potential adverse effects 
appear to translate into significantly lower rates of wom-
en with IBD opting to breastfeed. In a US study, only 29% 
of women with CD breastfed their babies compared to an 
average of 60% amongst unaffected women  [55] . 
 An overview of FDA pregnancy categories of the most 
important IBD drugs and their safety during pregnancy 
and lactation is provided in  tables 1 and  2 . Concerning 
thiopurines and biological therapy, we review a specific 
development below.
 Thiopurines 
 Six-mercaptopurine (6-MP) and its precursor azathio-
prine (AZA) are purine analogs which cross the placenta. 
Animal studies have observed risk of teratogenicity with 
an increased frequency of cleft lip and palate and skeletal 
and urogenital abnormalities. However, the low oral bio-
availability of these drugs associated with the fact that the 
immature liver of the fetus lacks the enzyme inosinate 
pyrophospohorylase necessary to convert AZA to its ac-
tive metabolite 6-MP, confer a protection to the fetus dur-
ing the organogenesis period. Besides this, the large and 
reassuring studies available on transplanted and rheuma-
tologic populations on AZA, allow us to consider these 
drugs as safe and compatible with pregnancy. In IBD,
different population studies  [56] and especially the 
CESAME cohort  [57] did not observe any increased risk 
of congenital abnormalities when exposed to thiopurines 
during pregnancy. A recent multicenter prospective study 
on more than 1,000 IBD pregnant patients  [58] , 324 of 
whom were on thiopurines, has confirmed this observa-
tion and did not show any increased risk of growth or 
developmental problem in the newborns. Lactation when 
on thiopurines is theoretically contraindicated, because 
of the potential risk of myelotoxicity, infection and pan-
creatitis for the newborn. But given the fact that the major 
part of 6-MP is excreted in the breast milk if the mother 
breastfeeds within 4 hours after drug intake, some au-
thors have proposed shifting the breastfeeding to 6 hours 
after the drug intake. In men, there is no need to stop the 
therapy before conception, as no effects on spermatogen-
esis have been observed. 
 Anti-TNF-  Therapy 
 Infliximab (IFX) and adalimumab (ADA) are mono-
clonal immunoglobulin G 1 (IgG1) antibodies, which 
are actively transported through the placenta via spe-
cific fetal receptors. This transport starts from the end 
of the first trimester but is weak at this time, so that the 
total IgG remains low until the end of the second trimes-
ter. From GW 30, an important transplacental passage 
takes place. Case studies, including 1 recently  [59] , have 
shown the detection of therapeutic levels of IFX in the 
newborns of mothers whose therapy was interrupted at 
GW 26. It is interesting to note that in these newborns, 
the IFX levels exceeded the levels detected in the moth-
er. Important to note is that these antibodies can stay in 
the newborn’s blood for six months after birth, which 
strictly contraindicates a vaccination with a live or at-
tenuated vaccine (i.e. measles, rubella, mumps, chicken-
pox, rotavirus or BCG). The recommendations are to 
wait at least 6 months or to obtain a negative dosage of 
the antibodies in the newborn blood before such vacci-
nations are administered. Although normal levels of 
lymphocytes B and T have been observed in these new-
borns, the long-term effects of anti-TNFs on their im-
mune system development are unknown. In regards to 
maternal-fetal complications, the main available regis-
tries  [47, 58, 60–62] include the recent GETAID (Groupe 
d’Etude Thérapeutique des Affections Inflammatoires 
du Tube Digestif) study  [60] involving IBD women di-
rectly exposed to anti-TNFs (of 136 pregnancies, 24 of 
the women were on a combotherapy with thiopurines) 
and the latest PIANO (Pregnancy in Inflammatory 
Bowel Disease and Neonatal Outcomes) study  [58] (pre-
liminary results: of 161 pregnancies directly exposed to 
anti-TNF, 59 of the women were on a combotherapy 
with thiopurines). These two studies, the largest to date, 
do not report an increased risk of adverse pregnancy and 
fetal outcome linked to anti-TNFs. In the GETAID 
study, the rate of complicated pregnancies (fetal losses 
whether spontaneous or therapeutic, prematurity and 
metabolic or infectious complications) was 30% includ-
ing miscarriages (9%) and prematurity (20%) among 
completed pregnancies. This is similar to earlier cohorts 
of IBD patients who had not used anti-TNFs. Neonatal 
complications ranged from 3 to 20% in the different 
studies. Accordingly, if the disease is in remission, stop-
ping IFX or ADA therapy at GW 30 is recommended. 
Otherwise, the therapy should be pursued until term, 
and precautionary measures should be applied concern-
ing vaccinations in the newborn.
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e 
in
 
in
ci
de
nc
e 
of
 o
ra
l c
le
fts
 [6
5]
, a
lth
ou
gh
 n
ot
 
re
pr
od
uc
ed
 in
 a
 p
ro
sp
ec
tiv
e 
st
ud
y 
[6
6]
.
N
ot
 su
ffi
ci
en
t d
at
a 
av
ai
la
bl
e 
fo
r b
ud
es
on
id
e,
 
on
ly
 sm
al
l c
as
e 
se
ri
es
 fi
nd
in
g.
N
o 
sig
ni
fic
an
t p
re
gn
an
cy
 ad
ve
rs
e e
ve
nt
s [
67
].
Pr
ef
er
re
d 
th
er
ap
y 
in
 c
on
ju
nc
tio
n 
w
ith
 5
-A
SA
 in
 c
as
e 
of
 
re
la
ps
e 
du
ri
ng
 p
re
gn
an
cy
. I
f p
os
sib
le
 d
o 
no
t u
se
 d
ur
in
g 
fir
st
 tr
im
es
te
r (
po
te
nt
ia
l r
isk
 o
f o
ra
l c
le
fts
). 
Sh
or
t-
ac
tin
g 
ag
en
ts
 (p
re
dn
iso
ne
, p
re
dn
iso
lo
ne
 o
r m
et
hy
lp
re
dn
iso
-
lo
ne
) a
re
 m
or
e 
ef
fic
ie
nt
ly
 m
et
ab
ol
iz
ed
 b
y 
th
e 
pl
ac
en
ta
 
an
d 
sh
ou
ld
 th
er
ef
or
e 
be
 p
re
fe
rr
ed
 (d
ex
am
et
ha
so
ne
 a
nd
 
be
ta
m
et
ha
so
ne
 a
re
 n
ot
 su
ffi
ci
en
tly
 m
et
ab
ol
iz
ed
). 
To
pi
ca
l 
st
er
oi
ds
 (e
ne
m
as
, f
oa
m
s o
r s
up
po
sit
or
ie
s)
 m
ay
 b
e 
us
ed
 
up
 to
 th
e 
th
ir
d 
tr
im
es
te
r (
th
er
ea
fte
r t
he
re
 is
 th
e 
po
te
nt
ia
l 
of
 p
re
m
at
ur
e 
de
liv
er
y)
.
O
nl
y 
lo
w
 le
ve
ls 
of
 st
er
oi
ds
 o
cc
ur
 in
 
br
ea
st
 m
ilk
 (d
ep
en
di
ng
 o
f t
he
 
pr
ep
ar
at
io
n 
be
tw
ee
n 
5 
an
d 
25
%
). 
H
en
ce
, a
n 
in
te
rv
al
 o
f a
t l
ea
st
 4
 h
 
be
tw
ee
n 
in
ta
ke
 a
nd
 b
re
as
tfe
ed
in
g 
is 
re
co
m
m
en
de
d.
 C
on
sid
er
 m
on
ito
ri
ng
 
fo
r a
dr
en
al
 in
su
ffi
ci
en
cy
 in
 in
fa
nt
 if
 
m
at
er
na
l d
os
es
 a
re
 h
ig
h 
[6
8]
.
Th
io
pu
ri
ne
s
(A
ZA
, 6
-M
P,
6-
th
io
gu
an
in
e)
D
D
es
pi
te
 c
at
eg
or
y 
D
, w
hi
ch
 is
 p
re
do
m
in
an
tly
 
ex
tr
ap
ol
at
io
n 
of
 a
ni
m
al
 d
at
a,
 A
ZA
 a
nd
 
6-
M
P 
ar
e 
ge
ne
ra
lly
 c
on
sid
er
ed
 sa
fe
.
Fe
ta
l a
bn
or
m
al
iti
es
 n
ot
 c
on
sis
te
nt
ly
 
in
cr
ea
se
d 
[6
9,
 7
0]
, a
lth
ou
gh
 a
 sl
ig
ht
 in
cr
ea
se
 
is 
su
gg
es
te
d 
by
 so
m
e 
st
ud
ie
s [
71
, 7
2]
.
In
 so
m
e 
[6
9,
 7
3]
, b
ut
 n
ot
 a
ll 
[7
4]
 st
ud
ie
s, 
sp
on
ta
ne
ou
s a
bo
rt
io
ns
, p
re
te
rm
 d
el
iv
er
y 
an
d 
lo
w
 b
ir
th
 w
ei
gh
t a
re
 re
po
rt
ed
.
N
o 
sa
fe
ty
 d
at
a 
fo
r 6
-t
hi
og
ua
ni
ne
, h
en
ce
 it
 is
 
no
t r
ec
om
m
en
de
d.
 
EC
C
O
 a
nd
 A
m
er
ic
an
 G
as
tr
oe
nt
er
ol
og
ic
al
 A
ss
oc
ia
tio
n 
re
co
m
m
en
d 
co
nt
in
ua
tio
n 
of
 A
ZA
 d
ur
in
g 
pr
eg
na
nc
y 
(t
he
re
 is
 a
 ri
sk
 o
f f
la
re
 w
ith
 st
op
pi
ng
). 
M
os
t s
af
et
y 
da
ta
 
ar
e 
fr
om
 th
e 
tr
an
sp
la
nt
at
io
n 
an
d 
rh
eu
m
at
ol
og
y 
lit
er
at
ur
e.
N
o 
in
os
in
at
e 
 p
ho
sp
ho
ry
la
se
, t
ha
t c
on
ve
rt
s A
ZA
 a
nd
 M
P 
to
 6
-t
hi
og
ua
ni
ne
 in
 th
e 
fe
tu
s; 
in
 a
dd
iti
on
 o
ra
l b
io
av
ai
l-
ab
ili
ty
 o
f A
ZA
 (4
7%
) a
nd
 6
-M
P 
(1
6%
) i
s g
en
er
al
ly
 lo
w
, 
bo
th
 m
ay
 o
ffe
r s
om
e 
pr
ot
ec
tio
n.
C
on
ce
rn
s o
f b
on
e 
m
ar
ro
w
 su
pp
re
ss
io
n 
an
d 
im
m
un
os
up
pr
es
sio
n 
(W
H
O
 
ad
vo
ca
te
s a
ga
in
st
 b
re
as
tfe
ed
in
g)
. 
H
ow
ev
er
, o
nl
y 
ve
ry
 sm
al
l a
m
ou
nt
s o
f 
A
ZA
 a
nd
 6
-M
P 
ap
pe
ar
 in
 b
re
as
t m
ilk
 
[7
5]
, m
aj
or
 p
ar
t w
ith
in
 4
 h
 a
fte
r d
ru
g 
in
ta
ke
 [7
6]
. N
o 
in
cr
ea
se
d 
ri
sk
 o
f s
ev
er
e 
in
fe
ct
io
ns
 w
as
 fo
un
d 
in
 a
 re
ce
nt
 st
ud
y 
[7
7]
. A
lth
ou
gh
 st
ill
 c
on
tr
ov
er
sia
l a
nd
 
di
sc
us
sio
n 
w
ith
 m
ot
he
r i
m
po
rt
an
t, 
br
ea
st
fe
ed
in
g 
is 
ge
ne
ra
lly
 su
pp
or
te
d 
by
 
EC
C
O
 g
ui
de
lin
es
 [4
].
A
nt
i-T
N
F
(I
FX
,
A
D
A
, C
TZ
)
B
G
en
er
al
ly
 c
on
sid
er
ed
 sa
fe
. M
os
t o
f t
he
 
lit
er
at
ur
e 
is 
fr
om
 rh
eu
m
at
ol
og
y.
 H
ow
ev
er
,
2 
re
ce
nt
 m
ul
tic
en
te
r s
tu
di
es
 in
 IB
D
 [5
8,
 6
0]
 
sh
ow
ed
 n
o 
in
cr
ea
se
d 
ri
sk
 o
f a
dv
er
se
 
pr
eg
na
nc
y 
an
d 
fe
ta
l o
ut
co
m
e 
w
ith
 a
nt
i-
TN
Fs
. I
n 
ad
di
tio
n,
 a
 re
ce
nt
 la
rg
e 
sin
gl
e-
ce
nt
er
 se
ri
es
 id
en
tif
ie
d 
sim
ila
r p
re
gn
an
cy
 
ou
tc
om
es
 in
 IB
D
 p
at
ie
nt
s o
n 
an
ti-
TN
F 
tr
ea
tm
en
t c
om
pa
re
d 
to
 p
re
gn
an
ci
es
 b
ef
or
e 
su
ch
 tr
ea
tm
en
t b
ec
am
e 
av
ai
la
bl
e,
 a
lth
ou
gh
 
pr
eg
na
nc
y 
ou
tc
om
e 
af
te
r d
ia
gn
os
is 
of
 IB
D
 
w
as
 w
or
se
 th
an
 p
ri
or
 to
 d
ia
gn
os
is 
[6
1]
.
IF
X
 a
nd
 A
D
A
 a
re
 Ig
G
1 
an
tib
od
ie
s, 
ac
tiv
el
y 
tr
an
sp
or
te
d 
th
ro
ug
h 
th
e 
pl
ac
en
ta
 la
te
 in
 th
e 
se
co
nd
 a
nd
 th
ir
d 
tr
im
es
-
te
r (
ac
tiv
e 
tr
an
sf
er
 o
f i
m
m
un
ity
 fr
om
 th
e 
m
ot
he
r t
o 
th
e 
ch
ild
) a
nd
 h
ig
he
r l
ev
el
s o
f I
FX
 a
nd
 A
D
A
 (c
om
pa
re
d 
to
 
se
ru
m
 in
 m
ot
he
rs
) a
re
 st
ill
 d
et
ec
ta
bl
e 
in
 th
e 
co
rd
-b
lo
od
 
se
ve
ra
l m
on
th
s a
fte
r b
ir
th
. A
lth
ou
gh
 th
e 
im
pl
ic
at
io
ns
 
he
re
ar
e 
st
ill
 a
re
 n
ot
 q
ui
te
 c
le
ar
, a
vo
id
an
ce
 o
f a
nt
i-T
N
F 
tr
ea
tm
en
t i
n 
th
e 
la
st
 tr
im
es
te
r i
s o
fte
n 
su
gg
es
te
d 
[4
], 
 un
le
ss
 th
e 
di
se
as
e 
is 
un
st
ab
le
 w
ith
 a
n 
in
cr
ea
se
d 
ri
sk
 o
f 
fla
re
 d
ur
in
g 
co
nc
ep
tio
n 
af
te
r d
ru
g 
w
ith
dr
aw
al
. A
ct
iv
e 
pl
ac
en
ta
l t
ra
ns
po
rt
 d
oe
s n
ot
 se
em
 to
 o
cc
ur
 w
ith
 C
TZ
(a
n 
an
tib
od
y 
fr
ag
m
en
t)
. L
ife
 v
ac
ci
ne
s a
re
 c
on
tr
ai
nd
ic
at
ed
 
in
 th
e 
fir
st
 6
 m
on
th
s a
fte
r d
el
iv
er
y 
(a
t l
ea
st
 in
 A
D
A
- a
nd
 
IF
X
-e
xp
os
ed
 b
ab
ie
s)
. C
as
e 
re
po
rt
 o
f f
at
al
 d
iss
em
in
at
ed
 
BC
G
 in
fe
ct
io
n 
af
te
r B
C
G
 v
ac
ci
na
tio
n 
an
d 
IF
X
 e
xp
os
ur
e 
[7
8]
. H
ow
ev
er
, a
dm
in
ist
ra
tio
n 
of
 in
ac
tiv
at
ed
 v
ac
ci
ne
s a
t 
no
rm
al
 sc
he
du
le
 is
 re
co
m
m
en
de
d 
an
d 
re
sp
on
se
 in
 a
nt
i-
TN
F-
ex
po
se
d 
ba
bi
es
 w
as
 sh
ow
n 
to
 b
e 
no
rm
al
.
IF
X
 is
 n
ei
th
er
 d
et
ec
te
d 
in
 b
re
as
t m
ilk
 
no
r i
n 
th
e 
in
fa
nt
’s 
se
ru
m
 le
ve
l. 
H
en
ce
, 
br
ea
st
fe
ed
in
g 
un
de
r I
FX
 tr
ea
tm
en
t 
ap
pe
ar
s a
cc
ep
ta
bl
e.
 
In
 c
on
tr
as
t, 
ve
ry
 lo
w
 le
ve
ls 
of
 A
D
A
 
w
er
e 
re
po
rt
ed
 in
 b
re
as
t m
ilk
, w
ith
 
qu
es
tio
na
bl
e 
re
le
va
nc
e 
(a
ch
ie
ve
m
en
t
of
 se
ru
m
 le
ve
ls 
in
 in
fa
nt
 is
 u
nl
ik
el
y,
 
du
e 
to
 p
re
su
m
pt
iv
e 
pr
om
pt
 p
ro
te
ol
yt
ic
 
di
ge
st
io
n 
in
 th
e 
st
om
ac
h)
. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
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D
ru
g 
FD
A
 c
la
ss
 in
pr
eg
na
nc
y
Sa
fe
ty
C
om
m
en
ts
 –
 u
se
 in
 p
re
gn
an
cy
C
om
m
en
ts
 –
 u
se
 d
ur
in
g 
br
ea
st
fe
ed
in
g
C
yc
lo
sp
or
in
e
C
Lo
w
 ri
sk
, a
lth
ou
gh
 m
os
t l
ite
ra
tu
re
 c
om
es
 
fr
om
 tr
an
sp
la
nt
at
io
n 
an
d 
rh
eu
m
at
ol
og
y.
N
o 
sig
ni
fic
an
t i
nc
re
as
e 
of
 m
al
fo
rm
at
io
ns
 
re
po
rt
ed
 in
 a
 m
et
a-
an
al
ys
is 
[7
9]
.
Se
ve
ra
l c
as
e 
re
po
rt
s d
ur
in
g 
pr
eg
na
nc
y 
in
 U
C
. I
n 
ge
ne
ra
l, 
th
e 
lo
w
 ri
sk
 o
f t
he
 d
ru
g 
ha
s t
o 
be
 w
ei
gh
ed
 a
ga
in
st
 th
e 
ri
sk
 
of
 a
cu
te
 se
ve
re
 d
ise
as
e 
or
 c
ol
ec
to
m
y.
 
C
yc
lo
sp
or
in
e 
ca
n 
be
 d
et
ec
te
d 
in
 b
re
as
t 
m
ilk
 [8
0]
. B
re
as
tfe
ed
in
g 
sh
ou
ld
 b
e 
av
oi
de
d 
(p
ot
en
tia
l t
ox
ic
ity
 a
nd
 im
m
u-
no
su
pp
re
ss
io
n 
in
 in
fa
nt
). 
Ta
cr
ol
im
us
C
M
os
t d
at
a 
co
m
e 
fr
om
 th
e 
tr
an
sp
la
nt
 li
te
ra
-
tu
re
, a
lth
ou
gh
 le
ss
 d
at
a 
av
ai
la
bl
e 
th
an
 w
ith
 
cy
cl
os
po
ri
ne
 [8
1]
.
So
 fa
r, 
on
ly
 1
 c
as
e 
of
 a
n 
un
ev
en
tfu
l p
re
gn
an
cy
 in
 U
C
 
re
po
rt
ed
 [8
2]
.
O
nl
y 
lim
ite
d 
hu
m
an
 d
at
a 
av
ai
la
bl
e,
 
po
te
nt
ia
l t
ox
ic
ity
. I
n 
a 
sin
gl
e 
ca
se
, o
nl
y 
a 
ve
ry
 lo
w
 le
ve
l o
f t
ac
ro
lim
us
 in
 b
re
as
t 
m
ilk
 w
as
 d
et
ec
te
d 
[8
3]
.
M
TX
,
th
al
id
om
id
e
X
Te
ra
to
ge
n 
is 
co
nt
ra
in
di
ca
te
d.
Ef
fe
ct
iv
e 
co
nt
ra
ce
pt
io
n 
is 
es
se
nt
ia
l. 
M
TX
 sh
ou
ld
 b
e 
st
op
pe
d 
in
 b
ot
h 
m
al
es
an
d 
fe
m
al
es
 a
t l
ea
st
 3
 m
on
th
s
(6
 m
on
th
s i
s b
et
te
r)
 p
ri
or
 to
 c
on
ce
pt
io
n.
 
In
 c
as
e 
of
 a
cc
id
en
ta
l p
re
gn
an
cy
, t
he
ra
pe
ut
ic
 a
bo
rt
io
n 
sh
ou
ld
 b
e 
di
sc
us
se
d,
 M
TX
 im
m
ed
ia
te
ly
 st
op
pe
d 
an
d 
a 
hi
gh
 d
os
e 
of
 fo
lic
 a
ci
d 
pr
es
cr
ib
ed
. A
bo
rt
io
n 
is 
ho
w
ev
er
 
no
t m
an
da
to
ry
, a
s n
or
m
al
 p
re
gn
an
cy
 o
ut
co
m
e 
ha
s b
ee
n 
re
po
rt
ed
 in
 so
m
e 
w
om
en
 e
xp
os
ed
 to
 M
TX
. 
M
TX
 is
 c
on
tr
ai
nd
ic
at
ed
. N
o 
da
ta
 o
n 
ex
cr
et
io
n 
of
 th
al
id
om
id
e 
in
 b
re
as
t m
ilk
 
av
ai
la
bl
e.
 
A
nt
ib
io
tic
s M
et
, F
Q
L 
su
ch
 a
s C
ip
,
am
ox
ic
ill
in
 8
A
C
L,
RI
X
, T
et
 su
ch
 a
s D
ox
,
SA
 su
ch
 a
s T
SM
.
B 
(M
et
, A
C
l)
C
 (C
ip
 a
nd
 o
th
er
 
FQ
L,
 T
SM
, R
IX
),
D
 (D
ox
)
M
et
 g
en
er
al
ly
 c
on
sid
er
ed
 sa
fe
, h
ow
ev
er
 ri
sk
 
of
 c
le
ft 
pa
la
te
 p
ro
ba
bl
y 
sli
gh
tly
 in
cr
ea
se
d 
if 
us
ed
 in
 th
e 
fir
st
 tr
im
es
te
r [
84
].
Po
te
nt
ia
l r
isk
 o
f d
am
ag
e 
of
 c
ar
til
ag
e 
an
d 
bo
ne
 d
ue
 to
 h
ig
h 
af
fin
ity
 w
ith
 F
Q
L.
A
s w
ith
 a
ll 
G
I m
ed
ic
at
io
ns
 in
 p
re
gn
an
cy
, s
ho
rt
es
t p
os
-
sib
le
 a
nt
ib
io
tic
 tr
ea
tm
en
t c
ou
rs
e 
po
ss
ib
le
 sh
ou
ld
 b
e 
us
ed
, 
e.
g.
 sh
or
t c
ou
rs
es
 o
f M
et
 o
r A
C
L 
m
ay
 b
e 
be
ne
fic
ia
l f
or
 
pe
ri
an
al
 d
ise
as
e 
or
 p
ou
ch
iti
s. 
FQ
L,
 a
nd
 if
 p
os
sib
le
 M
et
, 
sh
ou
ld
 n
ot
 b
e 
us
ed
 d
ur
in
g 
fir
st
 tr
im
es
te
r. 
A
vo
id
 T
et
 a
nd
 
SA
 d
ur
in
g 
en
tir
e 
co
ur
se
 o
f p
re
gn
an
cy
.
M
et
: l
im
ite
d 
hu
m
an
 d
at
a 
an
d 
po
te
nt
ia
l 
to
xi
ci
ty
 
FQ
L:
 li
m
ite
d 
hu
m
an
 d
at
a,
 b
re
as
t-
fe
ed
in
g 
pr
ob
ab
ly
 sa
fe
A
C
L:
 p
ro
ba
bl
y 
sa
fe
RI
X
: p
ro
ba
bl
y 
sa
fe
, a
lth
ou
gh
 so
 fa
r n
o 
hu
m
an
 d
at
a 
av
ai
la
bl
e
Te
t, 
D
ox
, T
SM
: s
af
e:
V
ar
ia
es
om
ep
ra
zo
le
,
pa
no
pr
az
ol
e,
la
ns
op
ra
zo
le
B,
 (C
: 
om
ep
ra
zo
le
)
Li
m
ite
d 
da
ta
 su
gg
es
tin
g 
lo
w
 ri
sk
A
nt
ac
id
s a
nd
 su
cr
al
fa
te
 a
re
 c
on
sid
er
ed
 sa
fe
H
um
an
 d
at
a 
no
t a
va
ila
bl
e 
(p
ot
en
tia
l 
to
xi
ci
ty
)
M
C
P,
 O
D
S,
 v
ita
m
in
 B
6
B,
 (C
: 
do
m
pe
ri
do
ne
)
C
on
sid
er
ed
 sa
fe
M
C
P:
 li
m
ite
d 
hu
m
an
 d
at
a,
 p
ot
en
tia
l 
to
xi
ci
ty
,
O
D
S:
 li
m
ite
d 
hu
m
an
 d
at
a,
 p
ro
ba
bl
y 
sa
fe
,
V
ita
m
in
 B
6: 
in
su
ffi
ci
en
t d
at
a,
 p
ro
ba
bl
y 
sa
fe
 in
 d
os
e 
no
t e
xc
ee
di
ng
 R
D
A
Lo
p,
 C
ho
B 
(L
op
), 
C
 (C
ho
)
Lo
p 
ca
n 
pr
ob
ab
ly
 b
e 
co
ns
id
er
ed
 sa
fe
C
oa
gu
lo
pa
th
y 
du
e 
to
 d
ec
re
as
ed
 fa
t a
bs
or
be
d 
vi
ta
m
in
s i
n 
in
fa
nt
 m
ay
 o
cc
ur
 (C
ho
)
Lo
p:
 li
m
ite
d 
da
ta
, p
ro
ba
bl
y 
sa
fe
C
ho
: c
om
pa
tib
le
M
et
 =
 M
et
ro
ni
da
zo
le
; F
Q
L 
= 
flu
or
oq
ui
no
lo
ne
s; 
C
ip
 =
 c
ip
ro
flo
xa
ci
n;
 A
C
L 
= 
cl
av
ul
an
ic
 a
ci
d;
 R
IX
 =
 ri
fa
xi
m
in
; T
et
 =
 te
tr
ac
yc
lin
es
; D
ox
 =
 d
ox
yc
yc
lin
es
; S
A
 =
 su
lfo
na
m
id
es
; T
SM
 =
 tr
im
e-
th
op
ri
m
-s
ul
fa
m
et
ho
xa
zo
le
; M
C
P 
= 
M
et
oc
lo
pr
am
id
e;
 O
D
S 
= 
on
da
ns
et
ro
n;
 L
op
 =
 L
op
er
am
id
e;
 C
ho
 =
 c
ho
le
st
yr
am
in
e.
Ta
b
le
 2
 (c
on
tin
ue
d)
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
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 Certolizumab 
 Certolizumab (CTZ) is a PEGylated Fab fragment of a 
monoclonal humanized antibody and not an entire IgG1 
antibody. It can therefore not actively cross the placenta 
and can thus be continued during the entire pregnancy. 
However, given its recent use, experience with CTZ dur-
ing pregnancy is limited. Nevertheless, no adverse preg-
nancy outcome has been reported.
 Regarding breastfeeding, it is still unclear whether an-
ti-TNFs are excreted in the breast milk or absorbed by it. 
Nevertheless, available studies do not report any toxicity 
associated with lactation, which makes anti-TNFs com-
patible with lactation.
 Conclusion 
 The major therapeutic advances observed in the field 
of IBD allow a large majority of patients to conceive and 
carry a pregnancy under safe conditions. The precondi-
tion to this is patient awareness and helping them to wait 
for and attain a remission before considering pregnancy, 
and to deploy all means to keep them in remission during 
the gestational period.  Intensive treatment of these pa-
tients, if deemed necessary, is legitimate, as the expected 
benefits for the mother and fetus clearly outweigh the 
eventual risks associated with the therapies. We maintain 
that the majority of therapies are safe during pregnancy. 
The question of the long-term impact of immunomodu-
lators and anti-TNFs on the newborn immunity of new-
borns is still not clear.
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